No retraction, correction or concern found when last checked on Oct 17, 2026.

Renal ischemia/reperfusion injury; from pathophysiology to treatment.

Maryam Malek, Mehdi Nematbakhsh

PubMed · 2015 · Review

doi:10.12861/jrip.2015.06

Abstract

Ischemia/reperfusion injury (IRI) is caused by a sudden temporary impairment of the blood flow to the particular organ. IRI usually is associated with a robust inflammatory and oxidative stress response to hypoxia and reperfusion which disturbs the organ function. Renal IR induced acute kidney injury (AKI) contributes to high morbidity and mortality rate in a wide range of injuries. Although the pathophysiology of IRI is not completely understood, several important mechanisms resulting in kidney failure have been mentioned. In ischemic kidney and subsequent of re-oxygenation, generation of reactive oxygen species (ROS) at reperfusion phase initiates a cascade of deleterious cellular responses leading to inflammation, cell death, and acute kidney failure. Better understanding of the cellular pathophysiological mechanisms underlying kidney injury will hopefully result in the design of more targeted therapies to prevent and treatment the injury. In this review, we summarize some important potential mechanisms and therapeutic approaches in renal IRI.

Shown for reading. Its publisher allows quoting it, not republishing it.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

Implication for health policy/practice/research/medical education:

1Renal injury associated with ischemia/reperfusion results from a dynamic process involving inflammation and some mediators in a complex interaction. Formation of oxidative stress and lipid peroxidation seems to be major factors which promotes the inflammation process during ischemia/reperfusion injury. A better understanding of the pathophysiology and therapeutic approach underlying the functional defects found in ischemic acute renal failure will also require that we take into account the complexity of illness.

Introduction

2Ischemia/reperfusion injury (IRI) is characterized by restriction of blood supply to an organ followed by restoration of blood flow and re-oxygenation. The inevitable injuries may occur after infarction, sepsis and organ transplantation and this phenomena exacerbate tissue damage by initiating an inflammatory cascade including reactive oxygen species (ROS), cytokines, chemokines, and leukocytes activation. In the kidney, IRI contributes to pathological conditions called acute kidney injury (AKI) that is a clinical syndrome with rapid kidney dysfunction and high mortality rates. The pathophysiology of IRI in kidney is very complex but some pathological pathways such as activation of neutrophils, release of reactive oxygen species and other inflammatory mediators including adhesion molecules and a variety of cytokines are involved. Studies have demonstrated the beneficial effects of different agents in combat with IRI, for example, doxycycline through reducing the level of pro-inflammatory cytokines, leptin by decreasing tumor necrosis factor alpha (TNF-α) level and increasing nitrite level, levosimendan through antioxidant and NO-related mechanisms, iloprost by suppression of lipid peroxidation and ascorbic acid via free radical scavenging and antioxidant activities.

Materials and Methods

3For this review, we used a variety of sources by searching through PubMed, Embase, Scopus and directory of open access journals (DOAJ). The search was performed by using combinations of the following key words and or their equivalents; renal injury, ischemia/reperfusion, AKI, reactive oxygen species. Manuscripts published in English as full-text articles and or as abstracts were included in the study.

Inflammation, leukocytes and adhesion molecules

4Inflammation as a common abnormality in kidney IRI seems to link the various cell types and playing an important role in its pathophysiology. Renal IRI triggers an inflammatory cascade that involved in more renal damages, so inhibition of inflammatory responses is a therapeutic approach to protect renal tissue. Chemokines are major mediators of the inflammation that regulate pro-inflammatory cytokine, adhesion molecule expression, leukocyte infiltration and activation. Pro-inflammatory cytokines and cytokines such as interleukin 6 (IL6) and TNFα play a major role in renal dysfunction of IRI. Activation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway mediated many pro-inflammatory cytokines that involved in progression of renal IRI. Dexmedetomidine (a highly selective α2-adrenoreceptor agonist) has a cytoprotective effect against renal IRI by inhibiting the phosphorylation of JAK/STAT proteins, reducing IL6 and TNFα that indicating its anti-inflammatory effects.

5Inflammatory mediators, ROS and cell adhesion molecules – intracellular adhesion molecule-1 (ICM-1) and P-selectin – recruit leukocytes and neutrophil infiltration into post ischemic tissue, then leads to enhanced leukocyte – endothelial interactions, which can promote injury, swelling of the endothelial cell and physically impede blood flow. Administration of ICM-1 antibody and the kidneys of ICM-1 knockout were protected from IRI in mice. Takada et al. showed that soluble P-selectin ligand attenuates post-ischemic neutrophil infiltration and injury by inhibiting the binding between P-selectin and leukotriene aggregation. In addition Patel et al. showed that endogenous 5-lipoxygenase metabolites enhanced the degree of renal injury, dysfunction, and inflammation caused by kidney IRI via expression of adhesion molecules while in 5-lipoxygenase knockout mice the renal IRI were ameliorated. Involvement of the inflammatory leukotriene pathway in IRI has been demonstrated in acute and chronic renal failure. Activation of leukocytes, especially neutrophils have an important role in the development of renal IRI. Neutrophils releases ROS, cytokines, proteases and other mediators that exceed IRI. Montelukast, zafirlukast and cysteinyl leukotriene receptor blockers, demonstrated protective effects on renal IRI through inhibition of neutrophil infiltration, suppression of adhesion molecules and lipid peroxidation.

6Many agents also have protecting effects on IRI through anti-inflammatory properties that mention in below. Nicotin is an anti-inflammatory cholinergic agonist, protect renal function after IRI by suppressing neutrophil infiltration, chemokines release and inflammation through an α7 nicotine acetylcholine receptor (α7nAchR). These renoprotective effects also reported in vagotomized animals and suggest that cholinergic agonists act directly within the kidney.

7Celastrol is a bioactive ingredient of chines herb “Tripterygium wilfordii” with anti-inflammatory and antioxidant activities that used in treating auto-immune diseases and chronic nephritis. Celastrol protect IRI by inhibiting neutrophil infiltration, lipid peroxidation and suppressing the induction of pro-inflammatory mediators synthesizes such as cyclooxygenase-2 (COX2) presumably by suppressing nuclear factor κB (NF-κB) signaling pathway. Besides controversial studies reported that celastrol promoted the kidney injury in renal IRI by upregulation of COX2 and prostaglandin E2 (PGE2) synthesis. As a conclusion it seems that inflammation, leukocytes and adhesion molecules are seriously involved in IRI process, and any agents that suppress inflammation process, or inhibit leukocytes and neutrophil infiltration may be suitable to attenuate the side effect of IRI in the kidney.

Oxidative stress and lipid peroxidation

8During IRI, the damaged tissue produce excessive amount of ROS cause oxidative stress which changes mitochondrial oxidative phosphorylation, ATP depletion, increase intracellular calcium and activation of membrane phospholipids proteases. The blood flow during reperfusion phase of IRI can produce oxygen free radicals which leads to lipid peroxidation as main pathway of free radical tissue injuries. Formation of free radicals develops renal tissue injury via peroxidation of membrane lipids and oxidative damage of proteins and DNA contribute to apoptosis and cell death. Also the down regulation of the antioxidant enzyme system such as catalase, superoxide dismutase, and glutathione peroxidase could be responsible for the pathophysiology of ischemia-reperfusion injury. Therefore inhibiting this pathway or prevention of free radical production is the strategy to protect the tissue during IRI.

9Studies have shown beneficial effects of free radical scavengers and antioxidants on IRI. Supplementations with antioxidants agents have protective effects in IRI induced oxidative stress. Oxygen free radical-mediated renal damage during the reperfusion period following ischemia was prevented by free radical scavengers and antioxidants activity of melatonin. In addition, inhibition of sympathetic nerve and decrease of catecholamine release may be other mechanisms that melatonin protects renal against IRI. Ulinastatin a potent protease inhibitor with antioxidant activity attenuate renal injury after ischemia by inhibiting apoptosis and neutrophils infiltration. Propofol with antioxidant activity reduce IRI through reduced lipid peroxidation, cytokines production, increased superoxide dismutase levels and up-regulation of bone morphogenetic protein-2 (BMP2) family that play important roles in diverse cell types. BMP2 down-regulation in IRI may contribute to an imbalance between cell proliferation and apoptosis thereby causing renal injury.

10Recent attentions to herbal products encourage scientists to investigate natural agents on IRI. Most of these products exert renoprotective effects on IRI by the radical scavenging and antioxidant activities such as picroliv, an antioxidant extract of Picrorhiza kurroa, naringin, a bioflavonoid and aqueous garlic extract. As conclusion, it is obvious that antioxidants agents could easily act against oxidative stress to protect the tissue against ischemia during IRI phase. However special attention is needed to use the dose of antioxidants, because some antioxidants showed toxic effects in particular dose.

Mitochondrial dysfunction

11During ischemia, mitochondrial oxidative phosphorylation is suppressed by lack of oxygen. This phenomena impaired ATP synthesis and diminished activity of cellular energy-dependent processes which could contribute to cell death. Mitochondria are the major source of intracellular ROS, and are also the primary target for ROS. ATP depletion stops pumping calcium out of the cell by Na/Ca2+antiporter channel therefore calcium accumulate in the cell and sodium accumulated within the cell cannot be removed by Na/K/ATPase. In addition intracellular calcium overload occurs from calcium redistribution of endoplasmic reticulum stores. Increased cytosolic calcium can activate calcium-dependent phospholipase A2, endonuclease and proteases within the cell that begin cell apoptosis. In the postischemic cell, mitochondria will be exposed to large amounts of Ca2+ and oxygen free radicals. These factors likely contribute to the progressive functional deterioration of mitochondria during the reperfusion phase. Therefore the ideal drug therapy needs to be targeted to mitochondria. A number of approaches have been used for targeted delivery of therapeutic agents to mitochondria and should demonstrate very powerful antioxidative properties inside the mitochondria under conditions of oxidative stress such as IRI. Gentamicin an antibacterial drug induce defect on mitochondrial oxidative phosphorylation and ATP/ADP ratio in reperfusion and therefore it causes renal damage in reperfusion phase more than ischemic phase.

Nitrite and nitric oxide

12Nitric oxide (NO) the endothelial cell product plays an important role in blood circulation. The half-life of NO in circulation is very short which limited its direct measurement, therefore its metabolites; nitrite and nitrate usually are measured. NO in low concentrations considered as renoprotective against renal ischemia due to its vasodilatory, antioxidant and anti-inflammatory properties, as well as its beneficial effects on cell signaling and inhibition of nuclear proteins.

13Renal IRI activate nitric oxide synthase (NOS) and increase the expression of NOS proteins. There are three different isoforms of NOS; endothelial NOS (eNOS) and neuronal NOS (nNOS) produce NO in short bursts in low concentrations for physiological purposes and inducible form of NOS (iNOS) which produces NO in high concentrations. It has been suggested that NO produced by iNOS is a toxic agent whereas eNOS is seen as a protective enzyme. NO produced in the renal proximal tubules in response to ischemic injury is mediated by iNOS.

14Studies have suggested that increased NO via iNOS activity during renal ischemia is deleterious to the kidney and inhibition of iNOS before IRI has a dramatic functional protection of kidneys against ischemic renal injury. Treatment with sildenafil citrate and tadalafil (phosphodiesterase type 5 inhibitors) decreased lipid peroxidation and myeloperoxidase (indicator of polymorphonuclear infiltration) in renal tissues via inhibition of iNOS expression. In addition, ischemia itself can provide endothelial dysfunction, and disturb formation of NO endothelial form of eNOS.

15The anion nitrite is an end product of NO metabolism. In hypoxia and ischemia conditions nitrite convert to NO by NOS and xanthine oxidase enzymes. Thus nitrite stored during normoxia and convert to NO in hypoxia conditions can be considered a NO buffer. Several recent reports have demonstrated NO and nitrite-mediated cytoprotection in IRI models. In addition of NO-dependent cytoprotection, nitrite may act via independent pathway.

Renin-angiotensin system

16Renin-angiotensin system (RAS) activation and angiotensin II (AgII) level elevation are the important risk factors in IRI. AgII make renal injury through constrict of renal vessels, enhance vascular sensitivity to sympathetic nerve stimulation, cause oxidative stress and apoptosis induction.

17RAS modulate inflammation in renal tissue with two opposite arms effects: angiotensin-converting enzyme (ACE)/AgII/AT1 receptor and angiotensin-converting enzyme 2 (ACE2)/(Ag-(1-7)/Mas receptor (deleterious and protective effect respectively). Renal ischemia appears to change the balance of RAS axis. Administration of the Mas receptor agonist, AVE0991, attenuated renal tissue damage and infiltration of leukocytes in the kidney IRI. ACE2 is a modulator of AgII levels and it convert AgII to Ag-(1-7) in renal tissue and antagonize many deleterious effects of AgII. New therapeutic strategy is led to activation of ACE2/Ag-(1-7)/Mas axis in renal IRI. Studies have demonstrated that angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers have protective effects on IRI in the kidney. Aliskiren (rennin inhibitor) can directly decrease rennin plasma activity and AgII level, has a protective effect on renal IRI through inhibition of RAS, oxidative stress and enhance the anti-apoptosis activity.

Complement system

18Many studies have shown the activation of complement system in various IR organs. Complement system activation releases a number of biologically active products (C4a, C3a, and C5a, C5b-9 and the anaphylatoxins) with proinflammatory and upregulation of adhesion molecules activity. C5a and C5b-9 have been shown to stimulate endothelial cell expression of selectins and intercellular adhesion molecule-1. The recognition of the involvement of complement has led to novel strategies to modulate IRI. Specific C5a receptor antagonist have shown protective effects against renal IRI. Also an interfering RNA (siRNA) that target complement 3 (C3) and caspase 3 genes reduced renal IRI. Zhou et al. in mice which deficient in C3, C4, C5, and C6 showed that C5b-9 mediated tubular cell damage was etiologic in IRI.

Ischemic preconditioning

19Ischemic preconditioning (IP) is a tolerance or adaptability of organ or tissue after primary exposure to a brief ischemia stimulus. The kidney has the ability to be preconditioned by a non-lethal period of ischemia, which makes it tolerate to subsequent ischemia-induced injury. In studies, renal IP was reduced cell lysis, apoptosis and lipid peroxidation with improvement of renal function in ischemic kidney. Reduction of adhesion molecules and inflammatory responses may be the mechanism of IP preventing effects. But In other studies, ischemic preconditioning appears to be mediated via pre-ischemic activation of adenosine receptors, specifically A1 adenosine receptors.

Conclusion

20Renal injury associated with ischemia/reperfusion results from a dynamic process involving inflammation and some mediators in a complex interaction. Formation of oxidative stress and lipid peroxidation seems to be major factors which promotes the inflammation process during IRI. A better understanding of the pathophysiology and therapeutic approaches underlying the functional defects found in ischemic acute renal failure will also require that we bear in mind the complexity of illness.

Authors’ contribution

21MM conducted literature review and wrote the article. MN planned and conducted literature review, and finalized it. All authors read and signed the manuscript.

Conflicts of interest

22The authors declared no competing interests.

Funding/Support

23None.

References 131

1.
The innate immune response in ischemic acute kidney injury. Clin Immunol. 2009;130:41-50.
Not in our library10.1016/j.clim.2008.08.016
2.
Pathophysiology of ischemic acute kidney injury. Nat Rev Nephrol. 2011;7:189-200.
Not in our library10.1038/nrneph.2011.16
3.
Acute kidney injury. Clin Evid 2011b. 2011.
Not in our library
4.
RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis · 2006
No notice
5.
Protective effects of doxycycline in ischemia/reperfusion injury on kidney. J Physiol Biochem. 2009;65:183-91.
Not in our library10.1007/bf03179069
6.
Effects of doxycycline on renal ischemia reperfusion injury induced by abdominal compartment syndrome. J Surg Res. 2011;167:113-20.
Not in our library10.1016/j.jss.2009.09.048
7.
Effect of leptin on renal ischemia-reperfusion damage in rats. J Physiol Biochem. 2004;60:79-84.
Not in our library10.1007/bf03168443
8.
Levosimendan protection against kidney ischemia/reperfusion injuries in anesthetized pigs. J Pharmacol Exp Ther. 2012;342:376-88.
Not in our library10.1124/jpet.112.193961
9.
The cytoprotective effects of verapamil and iloprost (ZK 36374) on ischemia/reperfusion injury of kidneys. Transpl Int. 1993;6:138-42.
Not in our library10.1007/bf00336356
10.
The protective effects of ascorbic acid against renal ischemia-reperfusion injury in male rats. Ren Fail. 2009;31:36-43.
Not in our library10.1080/08860220802546271
11.
The interaction between ischemia–reperfusion and immune responses in the kidney. J Mol Med (Berl). 2009;87:859-64.
Not in our library10.1007/s00109-009-0491-y
12.
Chemokine expression in renal ischemia/reperfusion injury is most profound during the reparative phase. International immunology. 2010;22:433-42.
Not in our library10.1093/intimm/dxq025
13.
Role of cytokines and chemokines in renal ischemia-reperfusion injury. Drug News Perspect. 2002;15:477-82.
Not in our library10.1358/dnp.2002.15.8.840067
14.
Double-Stranded RNA Induces IL-8 and MCP-1 Gene Expression via TLR3 in HaCaT-Keratinocytes. Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation Allergy). 2012;11:397-405.
Not in our library10.2174/187152812803251042
15.
Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J Pharmacol Exp Ther. 2005;312:1170-8.
Not in our library10.1124/jpet.104.078659
16.
Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol. 1999;162:196-203.
Not in our library10.1097/00005392-199907000-00068
17.
Blockage of JAK/STAT signalling attenuates renal ischaemia-reperfusion injury in rats. Nephrol Dial Transplant. 2008;23:91-100.
Not in our library10.1093/ndt/gfm509
18.
Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice · 2011
No notice
19.
α2-Adrenergic agonists protect against radiocontrast-induced nephropathy in mice. Am J Physiol Renal Physiol. 2008;295:F741-F8.
Not in our library10.1152/ajprenal.90244.2008
20.
Effect of dexmedetomidine on ischemia-reperfusion injury in rat kidney: a histopathologic study. Ren Fail. 2009;31:70-4.
Not in our library10.1080/08860220802546487
21.
Comparison of the effects of dexmedetomidine administered at two different times on renal ischemia/reperfusion injury in rats. Brazilian Journal of Anesthesiology (English Edition). 2013.
Not in our library10.1016/j.bjane.2013.06.002
22.
Dexmedetomidine protects against renal ischemia and reperfusion injury by inhibiting the JAK/STAT signaling activation · 2013
No notice
23.
Ischemia increases neutrophil retention and worsens acute renal failure: role of oxygen metabolites and ICAM 1. Kidney Int. 1995;48:1584-91.
Not in our library10.1038/ki.1995.451
24.
Nitric oxide prevents neutrophil-mediated acute renal failure. American Journal of Physiology-Renal Fluid and Electrolyte Physiology. 1997;41:F48.
Not in our library10.1152/ajprenal.1997.272.1.f48
25.
Cell biology and molecular mechanisms of injury in ischemic acute renal failure. Curr Opin Nephrol Hypertens. 2000;9:427-34.
Not in our library10.1097/00041552-200007000-00015
26.
The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney Inhibition by a soluble P-selectin ligand. J Clin Invest. 1997;99:2682.
Not in our library10.1172/jci119457
27.
Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proceedings of the National Academy of Sciences. 1994;91:812-6.
Not in our library10.1073/pnas.91.2.812
28.
Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest. 1996;97:1056.
Not in our library10.1172/jci118498
29.
Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. Mol Pharmacol. 2004;66:220-7.
Not in our library10.1124/mol.66.2.220
30.
Montelukast protects against renal ischemia/reperfusion injury in rats. Pharmacol Res. 2006;54:65-71.
Not in our library10.1016/j.phrs.2006.02.007
31.
Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. J Leukoc Biol. 2004;76:961-70.
Not in our library10.1189/jlb.0604338
32.
Chronic renal failure-induced multiple-organ injury in rats is alleviated by the selective CysLT1 receptor antagonist montelukast. Prostaglandins Other Lipid Mediat. 2007;83:257-67.
Not in our library10.1016/j.prostaglandins.2007.01.013
33.
The role of neutrophils in acute renal failure. Seminars in nephrology. 1998.
Not in our library
34.
Oxidative stress and neutrophil activation—the two keystones of ischemia/reperfusion injury. Int J Cardiol. 2002;86:41-59.
Not in our library10.1016/s0167-5273(02)00189-4
35.
Leucocyte adhesion molecules in ischaemic renal injury: kidney specific paradigms? Clin Exp Pharmacol Physiol. 1998;25:286-91.
Not in our library10.1111/j.1440-1681.1998.t01-1-.x
36.
Cysteinyl leukotriene receptor antagonism alleviates renal injury induced by ischemia-reperfusion in rats. J Surg Res. 2012;178:e25-e34.
Not in our library10.1016/j.jss.2012.02.022
37.
Nicotine protects kidney from renal ischemia/reperfusion injury through the cholinergic anti-inflammatory pathway. PloS One. 2007;2:e469.
Not in our library10.1371/journal.pone.0000469
38.
Cholinergic agonists attenuate renal ischemia–reperfusion injury in rats. Kidney Int. 2008;74:62-9.
Not in our library10.1038/ki.2008.94
39.
Celastrol protects kidney against ischemia–reperfusion-induced injury in rats. J Surg Res. 2014;186:398-407.
Not in our library10.1016/j.jss.2013.07.048
40.
Pretreatment with paricalcitol attenuates inflammation in ischemia–reperfusion injury via the up-regulation of cyclooxygenase-2 and prostaglandin E2. Nephrol Dial Transplant. 2013;28:1156-66.
Not in our library10.1093/ndt/gfs540
41.
Postischemic renal injury due to oxygen radicals. Curr Opin Nephrol Hypertens. 1993;2:625-35.
Not in our library10.1097/00041552-199307000-00014
42.
The cell biology of reperfusion injury in the kidney. J Investig Med. 1994;42:632.
Not in our library
43.
Mechanisms of ischemic acute renal failure. Kidney Int. 1993;43:1160-78.
Not in our library10.1038/ki.1993.163
44.
Oxygen free radicals in ischemic acute renal failure in the rat. J Clin Invest. 1984;74:1156.
Not in our library10.1172/jci111524
45.
Free radicals as mediators of tissue injury and disease. Crit Rev Toxicol. 1993;23:21-48.
Not in our library10.3109/10408449309104073
46.
Expression of antioxidant enzymes in rat kidney during ischemia-reperfusion injury. Mol Cell Biochem. 1993;125:97-104.
Not in our library10.1007/bf00936438
47.
Resveratrol, a polyphenol found in wine, reduces ischemia reperfusion injury in rat kidneys. J Cardiovasc Pharmacol. 2001;37:262-70.
Not in our library10.1097/00005344-200103000-00004
48.
Beneficial Effect of ALPHA-Tocopherol in Renal Ischemia-Reperfusion in Rats. The Japanese Journal of Pharmacology. 2001;87:164-6.
Not in our library10.1254/jjp.87.164
49.
Prevention of renal ischemia–reperfusion-induced injury in rats by picroliv. Biochem Pharmacol. 2000;59:1315-22.
Not in our library10.1016/s0006-2952(00)00268-9
50.
The long‐term outcome of post‐ischaemic acute renal failure in the rat I A functional study after treatment with SOD and sucrose. Acta Physiol Scand. 1990;138:25-33.
Not in our library10.1111/j.1748-1716.1990.tb08809.x
51.
Oxygen free radical induced damage in kidneys subjected to warm ischemia and reperfusion Protective effect of superoxide dismutase. Ann Surg. 1985;202:628.
Not in our library10.1097/00000658-198511000-00016
52.
Superoxide dismutase and catalase as therapeutic agents for human diseases a critical review. Free Radic Biol Med. 1990;8:201-9.
Not in our library10.1016/0891-5849(90)90092-w
53.
The protective effect of melatonin on renal ischemia-reperfusion injury in the rat. J Pineal Res. 2002 Mar;32:120-6.
Not in our library10.1034/j.1600-079x.2002.1848.x
54.
The protective effects of physiological and pharmacological concentrations of melatonin on renal ischemia-reperfusion injury in rats. Urol Res. 2003;31:188-93.
Not in our library10.1007/s00240-003-0314-5
55.
Impaired Basal Sympathetic Tone and α1-Adrenergic Responsiveness in Association With the Hypotensive Effect of Melatonin in Spontaneously Hypertensive Rats. Am J Hypertens. 1998;11:219-29.
Not in our library10.1016/s0895-7061(97)00401-9
56.
Effects of ulinastatin on renal ischemia-reperfusion injury in rats. Acta Pharmacol Sin. 2004;25:1334-40.
Not in our library
57.
Effects of propofol on renal ischemia/reperfusion injury in rats. Exp Ther Med. 2013;6:1177-83.
Not in our library10.3892/etm.2013.1305
58.
Protective effects of propofol against ischemia/reperfusion injury in rat kidneys. Ren Fail. 2010;32:578-83.
Not in our library10.3109/08860220903548940
59.
Effects of intravenous anesthetics on renal ischemia/reperfusion injury. Ren Fail. 2009;31:290-6.
Not in our library10.1080/08860220902779962
60.
Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res. 2004;95:773-9.
Not in our library10.1161/01.res.0000145728.22878.45
61.
Endothelial cells modulate osteogenesis in calcifying vascular cells. J Vasc Res. 2004;41:193-201.
Not in our library10.1159/000077394
62.
Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress stimulates an inflammatory response. J Biol Chem. 2003;278:31128-35.
Not in our library10.1074/jbc.m300703200
63.
BMP‐2 suppresses renal interstitial fibrosis by regulating epithelial–mesenchymal transition. J Cell Biochem. 2011;112:2558-65.
Not in our library10.1002/jcb.23180
64.
The effect of naringin, a bioflavonoid on ischemia-reperfusion induced renal injury in rats. Pharmacol Res. 2004;50:187-93.
Not in our library10.1016/j.phrs.2004.01.007
65.
Protective effect of aqueous garlic extract against renal ischemia/reperfusion injury in rats. J Med Food. 2005;8:319-26.
Not in our library10.1089/jmf.2005.8.319
66.
RETRACTED: The effect of quercetin, a bioflavonoid on ischemia/reperfusion induced renal injury in rats. Arch Med Res. 2004;35:484-94.
Not in our library10.1016/j.arcmed.2004.10.004
67.
Basic research: Kidney-specific antioxidant targeting for renal ischemic injury. Nat Rev Nephrol. 2012;8:194.
Not in our library10.1038/nrneph.2012.31
68.
Cellular and molecular derangements in acute tubular necrosis. Curr Opin Pediatr. 2005;17:193-9.
Not in our library10.1097/01.mop.0000152620.59425.eb
69.
Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention. Transplant Proc. 2008;40:3279-88.
Not in our library10.1016/j.transproceed.2008.10.004
70.
Regulation of cell death: the calcium–apoptosis link. Nat Rev Mol Cell Biol. 2003;4:552-65.
Not in our library10.1038/nrm1150
71.
Susceptibility of mitochondrial membranes to calcium and reactive oxygen species: implications for ischemic and toxic tissue damage. Prog Clin Biol Res. 1987;282:235-59.
Not in our library
72.
The role of mitochondria in oxidative and nitrosative stress during ischemia/reperfusion in the rat kidney. Kidney Int. 2007;72:1493-502.
Not in our library10.1038/sj.ki.5002568
73.
Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. J Am Soc Nephrol. 2011;22:1041-52.
Not in our library10.1681/asn.2010080808
74.
Potent mitochondria-targeted peptides reduce myocardial infarction in rats. Coron Artery Dis. 2007;18:215-20.
Not in our library10.1097/01.mca.0000236285.71683.b6
75.
Control of mitochondrial metabolism by the ATPADP ratio. Biochem Biophys Res Commun. 1978;83:1260-6.
Not in our library10.1016/0006-291x(78)91357-8
76.
Regulation of cellular metabolism by intracellular phosphate. Biochimica et Biophysica Acta (BBA)-Bioenergetics. 1977;462:20-35.
Not in our library10.1016/0005-2728(77)90186-4
77.
Gentamicin effects on renal ischemia/reperfusion injury. Circ Res. 1992;70:20-8.
Not in our library10.1161/01.res.70.1.20
78.
Nitric oxide as an antioxidant. Arch Biochem Biophys. 1991;289:130-6.
Not in our library10.1016/0003-9861(91)90452-o
79.
Nitric oxide as antiinflammatory agent. Methods Enzymol. 1996;269:434-42.
Not in our library10.1016/s0076-6879(96)69044-2
80.
Nitric oxide mechanism of protection in ischemia and reperfusion injury. Investigative Surgery. 2009;22:46-55.
Not in our library10.1080/08941930802709470
81.
NO and NOS isoforms in the development of apoptosis in renal ischemia/reperfusion. Free Radic Biol Med. 2006;40:992-1003.
Not in our library10.1016/j.freeradbiomed.2005.10.046
82.
Expression of inducible nitric oxide synthase and nitrotyrosineduring the evolution of experimental pulmonary tuberculosis. Exp Toxicol Pathol. 2001;53:257-65.
Not in our library10.1078/0940-2993-00182
83.
A protective role for endothelial nitric oxide synthase in glomerulonephritis. Kidney Int. 2002;61:822-5.
Not in our library10.1046/j.1523-1755.2002.00227.x
84.
Nitric oxide in obstructive uropathy: role of endothelial nitric oxide synthase. J Urol. 2002;168:1801-4.
Not in our library10.1097/01.ju.0000027177.45171.e9
85.
Antisense oligodeoxynucleotides to inducible NO synthase rescue epithelial cells from oxidative stress injury. American Journal of Physiology-Renal Fluid and Electrolyte Physiology. 1996;39:F971.
Not in our library10.1152/ajprenal.1996.270.6.f971
86.
Duality of nitric oxide in acute renal injury. Seminars in nephrology. 1999.
Not in our library
87.
The effects of PDE5 inhibitory drugs on renal ischemia/reperfusion injury in rats. Mol Biol Rep. 2012;39:9775-82.
Not in our library10.1007/s11033-012-1843-1
88.
Role for endothelial nitric oxide synthase in nitrite-induced protection against renal ischemia–reperfusion injury in mice. Nitric Oxide. 2010;22:141-8.
Not in our library10.1016/j.niox.2009.10.010
89.
Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proceedings of the National Academy of Sciences. 2001;98:12814-9.
Not in our library10.1073/pnas.221381098
90.
Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions. FEBS letters. 1998;427:225-8.
Not in our library10.1016/s0014-5793(98)00430-x
91.
Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest. 2005;115:1232-40.
Not in our library10.1172/jci22493
92.
Early intravenous infusion of sodium nitrite protects brain against in vivo ischemia-reperfusion injury. Stroke. 2006;37(11):2744-50.
Not in our library10.1161/01.str.0000245116.40163.1c
93.
Nitrite-derived nitric oxide by xanthine oxidoreductase protects the liver against ischemia-reperfusion injury. Hepatobiliary Pancreat Dis Int. 2005;4:350-5.
Not in our library
94.
Nitrite-derived nitric oxide protects the rat kidney against ischemia/reperfusion injury in vivo: role for xanthine oxidoreductase. J Am Soc Nephrol. 2007;18:570-80.
Not in our library10.1681/asn.2006050450
95.
Nitrite as an intrinsic signaling molecule. Nat Chem Biol. 2005;1(5):245-6.
Not in our library10.1038/nchembio1005-245
96.
Role of AT1 angiotensin II receptors in renal ischemic injury. Am J Physiol Renal Physiol. 1998;274:F79-F90.
Not in our library10.1152/ajprenal.1998.274.1.f79
97.
Role of angiotensin-converting enzyme (ACE and ACE2) imbalance on tourniquet-induced remote kidney injury in a mouse hindlimb ischemia–reperfusion model. Peptides. 2012;36:60-70.
Not in our library10.1016/j.peptides.2012.04.024
98.
Angiotensin and thromboxane in the enhanced renal adrenergic nerve sensitivity of acute renal failure. J Clin Invest. 1990;86:1532.
Not in our library10.1172/jci114872
99.
Role of superoxide in modulating the renal effects of angiotensin II. Hypertension. 2003;42:1150-6.
Not in our library10.1161/01.hyp.0000101968.09376.79
100.
Angiotensin II-induced mitochondrial Nox4 is a major endogenous source of oxidative stress in kidney tubular cells. PloS One. 2012;7:e39739.
Not in our library10.1371/journal.pone.0039739
101.
Endoplasmic reticulum stress and C/EBP homologous protein-induced Bax translocation are involved in angiotensin II-induced apoptosis in cultured neonatal rat cardiomyocytes. Exp Biol Med (Maywood). 2012;237:1341-9.
Not in our library10.1258/ebm.2012.012041
102.
Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT1 receptor axis vs ACE2–angiotensin-(1–7)–Mas receptor axis. Hypertens Res. 2009;32(7):533-6.
Not in our library10.1038/hr.2009.74
103.
ACE2: more of Ang-(1–7) or less Ang II? Curr Opin Nephrol Hypertens. 2011;20:1-6.
Not in our library10.1097/mnh.0b013e3283406f57
104.
Intrarenal angiotensin and bradykinin peptide levels in the remnant kidney model of renal insufficiency. Kidney Int. 2001;59:1458-65.
Not in our library10.1046/j.1523-1755.2001.0590041458.x
105.
Renoprotective effects of AVE0991, a nonpeptide Mas receptor agonist, in experimental acute renal injury. Int J Hypertens. 2012;2012.
Not in our library10.1155/2012/808726
106.
Angiotensin-converting enzyme 2 is a key modulator of the renin–angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens. 2011;20:62-8.
Not in our library10.1097/mnh.0b013e328341164a
107.
G-protein–coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation. 2005;111:1806-13.
Not in our library10.1161/01.cir.0000160867.23556.7d
108.
Losartan reverses fibrotic changes in cortical renal tissue induced by ischemia or ischemia-reperfusion without changes in renal function. Mol Cell Biochem. 2004;260:161-70.
Not in our library10.1023/b:mcbi.0000026068.38301.cf
109.
The preventive effect of captopril or enalapril on reperfusion injury of the kidney of rats is independent of angiotensin II AT1 receptors. Fundam Clin Pharmacol. 2003;17:595-8.
Not in our library10.1046/j.1472-8206.2003.00188.x
110.
Aliskiren: the first direct renin inhibitor available for clinical use. J Nephrol. 2011;24:541-9.
Not in our library10.5301/jn.5000008
111.
Protective effects of aliskiren on ischemia–reperfusion-induced renal injury in rats. Eur J Pharmacol. 2013;718:160-6.
Not in our library10.1016/j.ejphar.2013.08.038
112.
The complement system in myocardial ischaemia/reperfusion injury. Cardiovasc Res. 1994;28:437-44.
Not in our library10.1093/cvr/28.4.437
113.
The role of the complement system in ischemia-reperfusion injury. Shock. 2004;21:401-9.
Not in our library10.1097/00024382-200405000-00002
114.
Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and inflammation1. Transplantation. 2003;75:375-82.
Not in our library10.1097/01.tp.0000044455.05584.2a
115.
Intestinal reperfusion injury is mediated by IgM and complement. J Appl Physiol (1985). 1999;86(3):938-42.
Not in our library10.1152/jappl.1999.86.3.938
116.
Complement and renal ischemia-reperfusion injury. Am J Kidney Dis. 2001;38:430-3.
Not in our library10.1053/ajkd.2001.26113
117.
Wetsel RA, Kildsgaard J, Haviland DL. Complement anaphylatoxins (C3a, C4a, C5a) and their receptors (C3aR, C5aR/CD88) as therapeutic targets in inflammation. Therapeutic interventions in the complement system; 2000. p. 113-53.
Not in our library
118.
Comparative effect of C3a and C5a on adhesion molecule expression on neutrophils and endothelial cells. Inflammation. 1996;20:1-9.
Not in our library10.1007/bf01487740
119.
C5a-induced expression of P-selectin in endothelial cells. J Clin Invest. 1994;94:1147.
Not in our library10.1172/jci117430
120.
Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem. 1989;264:9053-60.
Not in our library
121.
A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int. 2003;63:134-42.
Not in our library10.1046/j.1523-1755.2003.00737.x
122.
Protection of renal ischemia injury using combination gene silencing of complement 3 and caspase 3 genes. Transplantation. 2006;82:1781-6.
Not in our library10.1097/01.tp.0000250769.86623.a3
123.
Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest. 2000;105:1363-71.
Not in our library10.1172/jci8621
124.
Ischemic tolerance and endogenous neuroprotection. Trends Neurosci. 2003;26:248-54.
Not in our library10.1016/s0166-2236(03)00071-7
125.
Regulatory T cells contribute to the protective effect of ischemic preconditioning in the kidney. Kidney Int. 2010;77:771-80.
Not in our library10.1038/ki.2010.12
126.
Ischemic postconditioning inhibits apoptosis after renal ischemia/reperfusion injury in rat. Transpl Int. 2008;21:364-71.
Not in our library10.1111/j.1432-2277.2007.00606.x
127.
Effect of ischemia preconditioning on renal ischemia/reperfusion injury in rats · 2012
Not checked
128.
Ischemic Preconditioning Attenuates Renal Ischemia-Reperfusion Injury by Inhibiting Activation of IKKβ and Inflammatory Response. Am J Nephrol. 2009;30:287-94.
Not in our library10.1159/000225928
129.
Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation. 1991;84:350-6.
Not in our library10.1161/01.cir.84.1.350
130.
Mechanisms of cardiac preconditioning: ten years after the discovery of ischemic preconditioning. J Surg Res. 1997;73:1-13.
Not in our library10.1006/jsre.1997.5187
131.
Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A1 and A3receptors. Am J Physiol Renal Physiol. 2000;278:F380-F7.
Not in our library10.1152/ajprenal.2000.278.3.f380

Cited by papers we hold 7

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.